- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07430202
Een DNAJB1-PRKACA-fusiekinase-peptidevaccin gecombineerd met glutamine-antagonist DRP-104, nivolumab en ipilimumab bij patiënten met gevorderd fibrolamellair carcinoom (FLC)
Een fase 1b-studie van een DNAJB1-PRKACA-fusiekinasepeptidevaccin gecombineerd met glutamine-antagonist DRP-104, nivolumab en ipilimumab voor patiënten met gevorderd fibrolamellair hepatocellulair carcinoom (FLC)
The purpose of this study is to determine whether the combination of a neoantigen vaccine targeting the DNAJB1-PRKACA fusion kinase in combination with DRP-104, Nivolumab and Ipilimumab is safe and yields a clinically compelling antitumor activity measured as based on objective response rate (ORR, assessed by RECIST 1.1). Secondary objectives include progression-free survival (PFS) and overall survival (OS).
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Colleen Apostol, RN
- Telefoonnummer: 410-614-3644
- E-mail: GIClinicalTrials@jhmi.edu
Studie Locaties
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21231
- Werving
- Johns Hopkins SKCCC
-
Contact:
- Colleen Apostal, RN
- Telefoonnummer: 410-614-3644
- E-mail: GIClinicalTrials@jhmi.edu
-
Hoofdonderzoeker:
- Marina Baretti, MD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Must have histologically confirmed FLC that is metastatic or unresectable.
- Presence of DNAJB1-PRKACA fusion transcript, assessed by RNA-sequencing, DNA-sequencing, or in situ hybridization in the archival tissue.
- Must have demonstrated radiographic progression on prior or current immunotherapy.
- Age ≥ 12 years.
- Patients < 18 years old must have a body weight ≥ 40 kg.
- ECOG (Eastern Cooperative Oncology Group) performance status of ≤2
- Patients must have adequate organ and marrow function defined by study-specified laboratory tests.
- Patients must have adequate kidney and liver function defined by study-specified laboratory tests.
- Must have measurable disease per RECIST 1.1
- Willingness to provide tissue and blood samples for mandatory translational research.
- Women of childbearing potential (WOCBP) must have a negative urine or serum pregnancy test.
- For both Women and Men, must use acceptable form of birth control while on study.
- Ability to understand and willingness to sign a written informed consent document.
Exclusion Criteria:
-
Patients with a history of prior treatment with checkpoint inhibitors, such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, anti-CTLA-4, or anti-LAG-3 antibodies.
-
Must have had chemotherapy or other systemic therapy or radiotherapy, as follows:
- Patients who have had chemotherapy, biological cancer therapy, or radiation 14 days prior to the first dose of study drug.
- Patients who have had surgery within 28 days of dosing of investigational agent, excluding minor procedures.
- Patients who have received other approved or investigational agents or device within 28 days of the first dose of study drug.
-
Patients who have not recovered from acute adverse events to grade ≤1 or baseline due to agents administered, with exception of grade 2 fatigue, rash, and endocrinopathy successfully managed hormone replacement therapy, or alopecia or stable neuropathy, unless approved by the IND Sponsor.
-
Patients who have received any non-oncology live vaccine therapy used for prevention of infectious diseases within 28 days of study treatment.
-
Known sensitivity to or history of allergic reactions attributed to compounds of similar chemical or biologic composition of polyinosinic-polycytidylic acid (Poly-ICLC) and/or DRP-104 and/or nivolumab and/or ipilimumab.
-
History of severe hypersensitivity reaction to any monoclonal antibody.
-
Has an active autoimmune disease.
-
Prior allogeneic stem cell transplantation or organ transplantation.
-
Has a diagnosis of immunodeficiency.
-
Systemic corticosteroids at immunosuppressive doses.
-
Subjects with interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected drug-related pulmonary toxicity.
-
Has a pulse oximetry of <92% on room air or is on supplemental home oxygen.
-
Active or untreated brain metastases or leptomeningeal metastases.
-
Uncontrolled intercurrent active medical and/or psychiatric illness/social psychosocial problems that that would limit compliance with study requirements.
-
Uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina, cardiac arrhythmia, metastatic cancer, or psychiatric illness/social situations that would limit compliance with study requirements.
-
Pregnant or breastfeeding.
-
Has a known history of Human Immunodeficiency Virus (HIV)/AIDS.
-
Has active hepatitis B. Patients with chronic or acute HBV infection.
-
Have had evidence of active or acute diverticulitis, intra-abdominal abscess, or GI obstruction which are known risk factors for bowel perforation should be evaluated for the potential need for additional treatment before coming on study.
-
Unwilling or unable to follow the study schedule for any reason.
-
Patient is at the time of signing informed consent a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
-
Evidence of clinical ascites.
-
Patients with QTc prolongation > 470 ms according to Fridericia formula.
-
Patients receiving potent inducers of CYP 3A4/5 (including but not limited to apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin and St. John's Wort) who cannot safely discontinue drug at least 14 days prior to Cycle 1 Day 1.
-
Have had an allergen hyposensitization therapy within 2 weeks prior to initiation of study treatment.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Arm A - DNAJB1-PRKACA-peptidevaccin met poly-ICLC-adjuvans, DRP-104, Nivolumab en Ipilimumab
|
Andere namen:
Andere namen:
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Number of participants experiencing grade 3 or above drug-related toxicities
Tijdsspanne: 4 years
|
When calculating the incidence of AEs, each AE (as defined by NCI CTCAE v6.0) will be counted only once for a given subject. |
4 years
|
|
Objective response rate (ORR) using immune Response Evaluation Criteria for Solid Tumors (RECIST 1.1)
Tijdsspanne: 4 years
|
ORR is defined as the percentage of patients achieving a complete response (CR) or partial response (PR) to DRP-104 in combination with DRP-104, Nivolumab and Ipilimumab, based on the immune Response Evaluation Criteria in Solid Tumors (RECIST 1.1) at any time during the study. CR = disappearance of all target lesions, PR is =>30percent decrease in sum of diameters of target lesions, progressive disease (PD) is >20percent increase in sum of diameters of target lesions, stable disease (SD) is <30percent decrease or <20percent increase in sum of diameters of target lesions. |
4 years
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Progression-free Survival (PFS) number of months according to RECIST (1.1) criteria.
Tijdsspanne: 4 years
|
PFS is defined as the number of months from the date of first treatment to disease progression (progressive disease [PD] or relapse from complete response [CR] as assessed using RECIST 1.1 criteria) or death due to any cause. Per RECIST 1.1 criteria, CR = disappearance of all target lesions, Partial Response (PR) is =>30% decrease in sum of diameters of target lesions, Progressive Disease (PD) is >20% increase in sum of diameters of target lesions, Stable Disease (SD) is <30% decrease or <20% increase in sum of diameters of target lesions. |
4 years
|
|
Overall survival (OS) of patients treated with study drug combination
Tijdsspanne: 4 years
|
OS is defined as the number of months from the first dose of study treatment to death from any cause. (OS will be censored on the date the subject was last known to be alive for subjects without documentation of death at the time of analysis). Estimation based on the Kaplan-Meier curve. |
4 years
|
Medewerkers en onderzoekers
Medewerkers
Onderzoekers
- Hoofdonderzoeker: Marina Baretti, MD, SKCCC • Johns Hopkins Medical Institution
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata per site
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata van het spijsverteringsstelsel
- Ziekten van het spijsverteringsstelsel
- Lever Ziekten
- Neoplasmata, glandulair en epitheel
- Carcinoom
- Lever neoplasmata
- Fibrolamellair hepatocellulair carcinoom
- Aminozuren, peptiden en eiwitten
- Eiwitten
- Antilichamen, monoklonaal, gehumaniseerd
- Antilichamen, monoklonaal
- Antilichamen
- Immunoglobulinen
- Immunoproteïnen
- Bloedeiwitten
- Serum -globulines
- Globulines
- Nivolumab
- Ipilimumab
- poly ICLC
Andere studie-ID-nummers
- J2622
- IRB00541955 (Andere identificatie: Johns Hopkins Medicine Institutional Review Board)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .